Although we did not measure LXR in these studies, it is known that increasing LXR activity in the intestine leads to decreased NPC1L1 and ACAT2 expression and increased expression of ABCG5/G8 and ABCA1, all of which would tend to mitigate the increased cholesterol burden of WD (28). Here, ACAT2 is linked to Wilson disease.